Parkinson's disease (PD) presents the second most common neurodegenerative disorder with largely unknown pathogenesis and inefficient therapeutic management. Accumulating data indicate that neuroinflammation, autophagy impairment, a-synuclein aggregation, and mitochondrial dysfunction may contribute to PD onset; however, the molecular mechanisms underlying these pathophysiological processes are still under elucidation. Interestingly, recent evidence has indicated that High-mobility group box 1 (HMGB1), a DNA-binding protein that can be actively secreted by inflammatory cells and passively released by necrotic cells may play a key role in PD pathogenesis. HMGB1 has been shown to participate in neuroinflammation, modulate autophagy and apoptosis as well as regulate gene transcription. Furthermore, therapeutic targeting of HMGB1 with either anti-HMGB1 antibodies or selective inhibitors, such as glycyrrhizin, has been shown to inhibit neurodegeneration in animal models. This review provides an update of recent data on the emerging role of HMGB1 in PD pathogenesis and discusses potential therapeutic approaches.
Parkinson's disease (PD) is the second most common neurodegenerative disorder affecting 1-2% of the population over 65 years of age (Lewis et al. 2016) . The etiology of PD still remains unknown, although existing data suggest that both genetic defects and environmental factors contribute to its onset (Warner and Schapira 2003) . The key pathological hallmarks of the disease are the formation of intracellular a-synuclein (SNCA) -containing protein aggregates termed Lewy bodies, as well as the gradual and irreversible degeneration of the dopaminergic neurons in the substantia nigra pars compacta (SNpc) in the midbrain, leading to progressive impairment of the nigrostriatal dopaminergic pathway (Ebrahimi-Fakhari et al. 2012) . PD is characterized by motor symptoms, such as bradykinesia, muscular rigidity, and resting tremor, as well as other pathological manifestations including depression and dementia (Sasaki et al. 2016) . The symptoms of PD usually become clinically apparent only when 50-60% of dopaminergic neurons have been already lost (Gao et al. 2011) . Dopamine replacement therapy with levodopa and dopamine receptor agonists is the current standard therapeutic scheme that provides symptomatic relief but is unable to inhibit the progressive neuronal loss and the continuation of clinical deterioration (Sasaki et al. 2016) . Moreover, a significant proportion of patients under long-term levodopa treatment develop complications, including motor fluctuations and dyskinesias that can be very disabling and may cause a major burden for their caregivers (Bonomo et al. 2017) .
Great efforts have been made toward the understanding of PD pathogenesis. Current studies indicate a dynamic interplay between multiple pathophysiological processes at a cellular level including oxidative stress, mitochondrial dysfunction, deregulation of autophagy as well as protein aggregation and neuroinflammation (Huang et al. 2017) . Two missense SNCA mutations (A53T and A30P) have been reported to increase SNCA aggregation in vitro and contribute to familial PD pathogenesis (Lindersson et al. 2004) . However, the underlying molecular mechanisms via which SNCA inclusions result in neurodegeneration have not been yet elucidated. Several studies have demonstrated that protein degradation pathways, such as the autophagy lysosomal pathway and ubiquitin-proteasome system may be involved in SNCA clearance (Pan et al. 2008) . Unfortunately, despite these recent advances, the etiology and the molecular mechanisms of neurodegeneration in PD still remain unclear, while a deeper understanding of intracellular signaling pathways and molecular targets is urgently needed (Gao et al. 2011) .
In search of biomarkers that may be involved in neuroinflammation and neurodegeneration processes associated with PD pathogenesis, emerging evidence points toward a critical role of High-mobility group box 1 (HMGB1). This is a highly conserved protein, expressed in the nucleus and cytoplasm of all cell types commonly acting as a damageassociated molecular pattern molecule (DAMP) that can be passively released by necrotic cells and actively secreted by inflammatory cells (Lotze and Tracey 2005) . DAMPs are recognized by pattern recognition receptors (PRRs) and are known to trigger inflammatory reactions. Additionally, HMGB1 can elicit pro-inflammatory responses via its interaction with multi-ligand receptors including the receptor for advanced glycation end products (RAGE) and toll-like receptor (TLR) 2 and 4 (Santoro et al. 2016) . In the nucleus, HMGB1 acts as a non-histone chromatin-binding protein, regulating several interactions of transcription factors with DNA as well as contributing to genome stability and DNA repair (Balliano et al. 2017 ). Several studies demonstrate the regulatory role of HMGB1 in cell proliferation, cell differentiation, necrosis as well as in maintaining the balance between apoptosis and autophagy (Lohani and Rajeswari 2016) . Consequently aberrant function of HMGB1 has been associated with many diseases including cancer, inflammatory disorders such as arthritis and colitis, infections, and traumatic injuries (Andersson and Tracey 2011) .
Regarding its role in neurodegenerative disorders, diffuse deposits of HMGB1 have been detected among dying neurons in animal models of Alzheimer's disease (Takata et al. 2004) . Moreover, HMGB1 has been shown to interact with polyglutamine (polyQ) protein, the causative factor of Huntington's disease, resulting in a reduction in polyQ aggregation and toxicity (Okazawa 2011) . Elevated anti-HMGB1 antibodies have been detected in the serum of patients suffering from amyotrophic lateral sclerosis (ALS) (Hwang et al. 2013) . Emerging evidence implicates HMGB1 in the regulation of neuroinflammation, autophagy, gene transcription, apoptosis, mitochondrial dysfunction, and oxidative stress associated with PD development. In this review, we will provide an update of current data on HMGB1 contribution to PD pathogenesis and discuss potential therapeutic approaches.
HMGB1 biology
HMGB1 belongs to the high-mobility group (HMG) family that is characterized by rapid electrophoretic mobility (Biscetti et al. 2017) . Its subcellular localization is regulated via acetylation and cellular activation state (Martinotti et al. 2015) . Nuclear HMGB1 is a structural chromatin protein modulating genome stability via relaxing nucleosome compactness and making chromatin structure more accessible. Moreover, HMGB1 may enhance DNA-binding capacity of several transcription factors, including nuclear factor-jB (NF-jB), p53, and the estrogen receptor (Martinotti et al. 2015) . Nuclear HMGB1 may also bind to DNA lesions and participate in DNA repair processes, such as mismatch repair. Finally, HMGB1 in the nucleus affects telomerase activity. Upon various stimuli, hyperacetylated HMGB1 can be translocated from the nucleus to the cytosol, stored in lysosomes and released extracellularly. Cellular necrosis leads to passive extracellular release of HMGB1, while inflammatory stimuli may trigger active release of HMGB1 from immune cells or astrocytes (Martinotti et al. 2015) . Extracellular HMGB1 can then interact with various receptors including RAGE and TLR2, TLR4, and TLR9 (Ding et al. 2017) . Upon binding to RAGE, HMGB1 can regulate cell growth, proliferation, and migration via activation of Mitogen Activated Protein Kinase (MAPK) and NF-jB pathways, while HMGB1-TLRs interaction mainly modulates inflammatory responses (Ding et al. 2017 ).
HMGB1 exhibits a critical role in PD-associated neuroinflammation
In recent years, neuroinflammation has emerged as a critical contributor to PD pathogenesis. Reactive microglia and inflammatory molecules have been found in SN of PD patients, and several cytokine polymorphisms have been reported as risk factors for PD onset (Wahner et al. 2007) . Microglia may exert beneficial effects on neuroprotection via debris removal and the secretion of neurotrophic factors (Schwartz 2002; Gao et al. 2011) . On the other hand, the secretion of potential cytotoxins by microglia could cause damage to dopaminergic neurons (Rogers et al. 2007) . Therefore, neuroinflammation is currently recognized as a double-edged sword in neurodegeneration, being able to exert both beneficial and detrimental effects on neurons (Nguyen et al. 2002) . However, little is known about the molecular mechanisms involved in these pathological processes.
HMGB1 can be actively secreted by inflammatory cells and passively released by necrotic cells, participating in inflammatory responses (Fig. 1) . It is therefore tempting to speculate that it may represent a potential candidate molecule linking neuroinflammation and neurodegeneration in PD. Indeed, HMGB1 can be released by both glial cells and degenerating neurons in the extracellular space (Gao et al. 2011; Sasaki et al. 2016) . A temporal pattern of HMGB1 release has been demonstrated, since activated astrocytes secrete HMGB1 in a relatively later stage compared to dying neurons that release HMGB1 acutely after 6-hydroxydopamine (6-OHDA) neurotoxicity (Sasaki et al. 2016) . Interestingly, HMGB1 has been shown to activate microglia in neuron-glial cultures to release neurotoxic and inflammatory molecules, such as TNF-a, IL-1b, and NO. However, addition of neutralizing anti-HMGB1 antibodies in neuronglial lipopolysaccharide (LPS)-, 1-methyl-4-phenylpyridinium (MPP+)-, or rotenone-treated cultures inhibits the degeneration of dopaminergic neurons (Gao et al. 2011) .
Consistent with this data, the intravenous administration of anti-HMGB1 monoclonal antibodies (mAbs) on a rat PD model suppressed significantly microglia activation and led to the preservation of dopaminergic neurons in SNpc. It further preserved dopaminergic terminals and dopamine levels in the striatum and consequently, in the nigrostriatal pathway (Sasaki et al. 2016) . Notably, these pathologoanatomical alterations reflected PD clinical improvement with preserved motor function been observed in the anti-HMGB1 mAbs-treated rats compared with the control group. Furthermore, the expression of the pro-inflammatory cytokines IL-1b and IL-6 was significantly reduced in the SN and in the striatum following anti-HMGB1 mAbs treatment. Moreover, the disruption of blood-brain barrier (BBB) and the elevated vascular permeability caused by 6-OHDA neurotoxicity was inhibited in the anti-HMGB1-treated group. Therefore, along with the direct suppression of cytokines in the rat brain, anti-HMGB1 administration prevented leakage in BBB, which is proposed to indirectly contribute to PD pathogenesis by allowing entry of various inflammatory or neurotoxic factors in the brain (More et al. 2013) .
Regarding the underlying molecular mechanisms of HMGB1-mediated interconnection between neuroinflammation and neurodegeneration, its interaction with macrophage antigen complex 1 (Mac1) is suggested to play a critical role. HMGB1 has been shown to function as a DAMP when released extracellularly, interacting with PRRs and initiating an inflammatory response. Mac1, a molecule of the b2 integrin family that acts as a PRR, has been found to be highly expressed in PD brains and seems to be essential for the microglia-mediated neurotoxicity induced by SNCA (Andres-Mateos et al. 2007) . In this context, HMGB1 has been revealed to bind to microglial Mac1 and this interaction may lead to microglia activation and neurodegeneration (Gao et al. 2011 ). More specifically, upon Mac1 binding, HMGB1 activates NADPH oxidase and NF-jB signaling pathway in microglia, thus inducing the production of neurotoxic and pro-inflammatory molecules, including TNF-a, IL-1b, and NO. Furthermore, HMGB1-Mac1 interaction enhances degeneration of dendrites, decreases dopamine uptake and reduces the number of dopaminergic neurons (Gao et al. 2011) .
Despite the typical intracellular localization of SNCA, it can also be secreted extracellularly via exocytosis, triggering microglia activation. In turn, microglial cells can efficiently phagocytose extracellular SNCA aggregates (Deleidi and Maetzler 2012). Therefore, although HMGB1-induced neuroinflammation seems to enhance dopaminergic degeneration, it may also reduce phagocytosis of extracellular SNCA aggregates. Importantly, microglial clearance of SNCA has been reported to be at least partially mediated by activation of TLR4, one of the main receptors of HMGB1 (Stefanova et al. 2011) . Consequently, the exact role and final outcome of HMGB1 function in PD neuroinflammation needs to be further investigated.
Taken together, these studies highlight the important contribution of HMGB1 signaling in neuroinflammation, inflammation-induced oxidative stress, and neurodegeneration. It can be therefore speculated that HMGB1 may present the missing link between these dynamic pathophysiologic processes in PD pathogenesis, possibly maintaining the vicious cycle between dying neurons and deregulated neuroinflammation leading to PD progression (Gao et al. 2011 ).
HMGB1-RAGE axis regulates L-Dopa production
HMGB1 has been recently reported to play a regulatory role on tyrosine hydroxylase (TH) activity, an enzyme that catalyzes the conversion of L-tyrosine to L-dopa (Kim et al. 2017) . Specifically, addition of recombinant HMGB1 in the dopaminergic neuronal progenitor cell line, SN4741 increased TH mRNA expression via its interaction with RAGE. HMGB1 was also able to rescue the MPP+-induced reduction in TH mRNA levels. Interestingly, up-regulation of TH expression was found to be mediated via the activation of c-Jun N-terminal kinase (JNK) downstream pathway upon HMGB1-RAGE interaction. Given the fact that the reduced activity of TH leads to decreased dopamine in the nigrostriatal pathway, it is of great interest that the extracellular levels of HMGB1 may critically affect dopamine levels and motor symptoms in PD, via its interaction with RAGE. Additionally, several studies have shown that JNK activation may contribute to PD pathogenesis by promoting neuronal cell death (Peng and Andersen 2003; Wang et al. 2004 Wang et al. , 2009 ). Thus, future functional studies are needed to investigate the effects of JNK activation upon HMGB1-RAGE binding in dopaminergic degeneration and other pathophysiological aspects of PD.
HMGB1 regulates autophagy in PD
It has been previously established that HMGB1 plays an important role in the regulation of apoptosis and autophagy (Tang et al. 2010) . Upon cell triggering by autophagic stimuli, HMGB1 can be translocated from the nucleus to the cytosol, where it binds to the mammalian autophagy protein, Beclin1. Beclin1 is a B-cell lymphoma 2 (Bcl-2)-homology (BH)-3 domain only protein that coordinates the autophagic proteins' localization and trafficking to a pre-autophagosomal structure via class III type phosphoinositide 3-kinase (PI3KC3)/Vps34 interaction.
HMGB1-Beclin1 binding results in Beclin1-Bcl-2 dissociation, translocation of Beclin1 to autophagosome, and initiation of autophagy via the Beclin1-Vps34 complex. Emerging evidence suggests that deficient autophagy contributes to SNCA aggregation and HMGB1-Beclin1 interaction may present a potential contributing factor to autophagy impairment observed in PD (Song et al. 2014; Huang et al. 2017) . Interestingly, it has been observed that HMGB1 can bind to SNCA and exert significant effects on autophagy regulation in inducible PC12 (iPC12) cell lines overexpressing SNCA (Song et al. 2014) . In particular, nuclear and cytosolic endogenous HMGB1 was found to bind to endogenous and over-expressed wild-type (WT) and mutant (A53T) SNCA. Upon HMGB1-SNCA interaction, HMGB1 translocation from the nucleus to the cytosol was blocked. Notably, HMGB1-SNCA binding inhibited Beclin1-HMGB1 interaction and enhanced Beclin1-Bcl-2 interaction, impairing the SNCA-induced autophagy. Another recent study has suggested that HMGB1 can deregulate autophagy in rotenone-induced PD cell models via suppressing the formation of Beclin1-Vps34 complex (Huang et al. 2017) . Under normal conditions, Beclin1 has been reported to interact with Vps34 and not with HMGB1. However, upon rotenone exposure, HMGB1 is over-expressed and interacts with a higher affinity to Beclin1 than to Vps34. Consequently, Beclin1-Vps34 complex formation is inhibited, resulting in autophagy impairment (Huang et al. 2017) .
However, another study reported that high HMGB1 levels may enhance starvation-induced autophagy in PC12 cells over-expressing WT or mutant SNCA, by inducing more autophagic vesicles in these cells (Wang et al. 2016 ). In addition, HMGB1 over-expression resulted in the downregulation of SNCA levels. Therefore, HMGB1 may restore SNCA-mediated autophagy inhibition, resulting in the enhancement of SNCA degradation. It is also important to mention that extracellular HMGB1 did not affect the starvation-induced autophagy in this study, indicating that the regulatory effects of HMGB1 were probably RAGE-or TLR-independent (Wang et al. 2016) . These data agree with previous studies where HMGB1 ablation was reported to inhibit autophagy under oxidative stress both in vitro and in vivo (Tang et al. 2010 (Tang et al. , 2011b .
These contradictory data could be attributed to different types of cell lines used, as well as to variable conditions of autophagy induction. The molecular processes underlying autophagy under basal conditions may differ from those under SNCA or stress stimulation, such as starvation. Moreover, the level of intracellular oxidative stress, which may increase during starvation, for example, may affect significantly the regulatory role of HMGB1 in autophagy since oxidation of the cysteines at positions 23 and 45 of HMGB1 is required for Beclin1 binding (Tang et al. 2010) .
These data together indicate that HMGB1 may be critically related to autophagy regulation and consequently SNCA aggregation in PD; however, further studies are needed to elucidate the underlying molecular mechanisms.
HMGB1 is involved in cell viability and apoptosis in PD
Apoptotic cell death of dopaminergic neurons in SNpc has been associated with PD pathogenesis, as evidenced by the presence of a pro-apoptotic microenvironment and apoptosis detected in the nigrostriatal region of postmortem brain of animal models and PD patients (Lev et al. 2003) .
Interestingly, HMGB1 has been demonstrated to exert significant effects in cell viability and apoptosis in rotenoneinduced PD cell models. More specifically, HMGB1 overexpression can decrease the cell viability and increase the apoptotic rate of human neuroblastoma cells after rotenone treatment. Furthermore, it was demonstrated that HMGB1 over-expression contributed to the destruction of nuclear structure and shrinkage of these cells. Notably, these morphological cellular alterations, as well as the apoptotic rates were partially prevented by HMGB1 suppression following siRNA-HMGB1 pre-treatment (Huang et al. 2017) .
HMGB1 can interact with SNCA and may impair gene transcription
A well-established hallmark of PD is the SNCA aggregates in Lewy bodies. However, the pathogenic mechanisms by which SNCA accumulation leads to neurodegeneration have not yet been elucidated. Abnormal cytosolic aggregated SNCA has been reported to inhibit the normal cellular regulation of gene expression, via sequestration of transcription factors in the cytosol, such as Elk-1 (Iwata et al. 2001) and NF-jB (Togo et al. 2001) . Given the important role of HMGB1 in the regulation of gene transcription and genome stability, it has been proposed that the binding of HMGB1 to aggregated SNCA could represent a potential mediator of the damaging effects and the toxic gain of function of aggregated SNCA (Lindersson et al. 2004) .
Indeed, HMGB1 protein was found co-localized with SNCA filaments in the cytoplasm of rotenone-induced PD cell models (Huang et al. 2017) , as well as in brain tissue specimens of PD patients (Lindersson et al. 2004) . HMGB1 was demonstrated to bind preferably to aggregated SNCA, via its DNA-binding domain that consists of the two basic HMG boxes (HMG domains A and B) . This interaction was dependent on the C-terminal segments of SNCA and it did not require amyloid-type filament characteristics (Lindersson et al. 2004) . Upon this binding, the ability of HMGB1 to interact with double-stranded DNA was found to be impaired. Consequently, aggregated SNCA-HMGB1 interaction was shown to inhibit normal nuclear functions of HMGB1 including regulation of gene expression, nucleosome stabilization, and DNA repair. Consequently, the mislocation of HMGB1 and the subsequent loss of its normal nuclear function may contribute to neurodegeneration. Among others, HMGB1 has been demonstrated to affect gene transcription mediated by steroid receptors, such as the estrogen receptor (Lindersson et al. 2004 ) and therefore, the potential neuroprotective effects of estrogens in neurodegenerative disorders need to be further investigated.
Additionally, HMGB1 was shown to regulate SNCA expression recently. HMGB1 over-expression enhanced SNCA expression in rotenone-induced PD cell models, while HMGB1 suppression led to decreased SNCA expression. Moreover, the regulatory effect of HMGB1 on SNCA expression levels was enhanced by exposure to rotenone (Huang et al. 2017) . In order to clarify the interplay between aggregated SNCA and HMGB1, the effects of their interaction should be investigated separately in the nucleus and the cytosol, as well as in the extracellular space.
HMGB1 is implicated in mitochondrial dysfunction observed in PD
Accumulating evidence suggests that mitochondrial dysfunction is tightly linked to PD pathogenesis, via several mechanisms, including mitochondrial DNA mutations, electron transport chain impairment, changes in mitochondrial dynamics and morphology, as well as abnormal calcium homeostasis (Subramaniam and Chesselet 2013) . It has been recently reported that rotenone treatment may lead to mitochondrial deformation and swelling of the mitochondrial cristae in human neuroblastoma cell cultures. These events were enhanced by HMGB1 over-expression, while HMGB1 suppression via siRNA-HMGB1 could partially reduce these mitochondrial alterations (Huang et al. 2017) . It is therefore suggested that HMGB1 could play a critical role in mitochondrial dysfunction observed in PD and the underlying molecular mechanisms need further elucidation.
Clinical significance and therapeutic potential of HMGB1 in PD
Several recent studies support the implication of HMGB1 in PD pathogenesis. Elevated HMGB1 protein levels have been detected in the postmortem midbrain tissues as well as in the CSF and serum of PD patients in comparison with controls (Santoro et al. 2016) . HMGB1 protein was found located mainly in the cytosol in PD cases, while commonly present in the nucleus of controls indicating that HMGB1 translocation is associated with PD pathology (Santoro et al. 2016) . In this context, a recent study revealed that rotenone exposure led to the translocation of HMGB1 in human neuroblastoma cells (SH-SY5Y) from the nucleus to the cytoplasm (Huang et al. 2017) . Furthermore, HMGB1 serum levels -but not cerebrospinal fluid (CSF) -were negatively correlated with the onset age and positively associated with the duration of the disease. No correlation was found between Hoehn and Yahr staging of the disease and HMGB1 levels (Santoro et al. 2016) . However, the positive association of HMGB1 levels with disease duration suggests that circulating HMGB1 in PD patients probably derives not only from the dopaminergic neurons, but also from another cellular source and can be used as a potential biomarker (Santoro et al. 2016) .
In view of the above, pharmacological targeting of HMGB1 could be a reasonable approach to attack PD progression. Emerging evidence supports the view that neutralizing anti-HMGB1 mAbs may exert significant neuroprotective effects in PD. In particular, as discussed above, the intravenous administration of anti-HMGB1 mAbs in rat models of PD significantly suppressed neuroinflammation, rescued dopaminergic neurons from neurotoxicity against 6-OHDA, and protected BBB disruption in the striatum. Furthermore, upon anti-HMGB1 mAbs treatment, HMGB1 was retained inside the nucleus and its levels were found decreased in both plasma and brain tissues. Notably, these pathophysiological changes were also accompanied by a significant reduction in PD motor symptoms, as demonstrated by the cylinder test as well as the amphetamineinduced rotation test (Sasaki et al. 2016) .
These observations are in agreement with another study showing that the administration of anti-HMGB1 antibodies in murine PD models protected the dopaminergic neurons in SNpc against the parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity, which was reflected by the preservation of dopaminergic fibers and dopamine levels in the striatum after MPTP treatment (Santoro et al. 2016) . Furthermore, in the same study, anti-HMGB1 antibodies resulted in a significant reduction in RAGE and TNF-a, as well as decreased microglial activation and gliosis in the MPTP-treated mice. The study suggests that the observed HMGB1 effects caused by MPTP were probably RAGE dependent. Possible downstream pathways upon HMGB1/RAGE interaction may involve p38, SAPK/ JNK (Janus Kinase) MAP kinases, ERK 1/2 MAP kinases, the JAK/STAT (Signal Transducer and Activator of Transcription) pathway as well as other receptors, such as TLR-2, TLR-4, and Mac1 (Wahamaa et al. 2011; Santoro et al. 2016) . Subsequently, the anti-inflammatory and antidegenerative effects of anti-HMGB1 mAbs suggest that targeting HMGB1 should be a rational treatment approach against PD, deserving however further study.
Given the fact that HMGB1 is associated with a variety of diseases, from cancer to neurodegeneration, it is not surprising that in vivo evidence has shown that anti-HMGB1 antibodies may be effective for the treatment of other neurological disorders, such as epilepsy (Zhao et al. 2017) , traumatic brain injury (Okuma et al. 2012) , and ischemic stroke (Liu et al. 2007) . The underlying molecular mechanisms involve the protection against BBB disruption, the inhibition of HMGB1 translocation from nucleus to cytosol and the suppression of neuroinflammatory responses (Liu et al. 2007; Okuma et al. 2012; Zhao et al. 2017) . However, although HMGB1-specific antibody-based therapy has been proven successful in pre-clinical studies, long-term effectiveness and safety in humans has not been investigated yet. Importantly, their use may be hindered by the unwanted immunogenicity (Lundback et al. 2016 ) that could reduce their efficacy and cause important side effects, such as anaphylactic reactions (Knezevic et al. 2015) . Furthermore, infections such as reactivation of tuberculosis and progressive multifocal encephalopathy, drug-induced immune thrombocytopenia, autoimmune conditions, tumorigenesis, and cardiotoxicity are some of the possible side effects of monoclonal antibodies that should be cautiously taken into account in the clinical settings (Hansel et al. 2010) .
Another possible way of targeting HMGB1 is the use of molecules that directly bind to HMGB1 and inhibit its function, such as glycyrrhizin, a natural liquorice extract. Interestingly, a recent study reported that upon glycyrrhizin treatment, MPTP-induced neurotoxicity in mice was significantly decreased in a dose-dependent manner. More specifically, dopaminergic neurons in SNpc were rescued and dopamine levels were preserved in the presence of glycyrrhizin (Santoro et al. 2016) . However, glycyrrhizin displays a wide variety of functions, including the inhibition of phospholipase A2 activity, the suppression of platelet aggregation, and the inhibition of 11-beta-hydroxysteroid dehydrogenase, an enzyme that converts cortisol to cortisone (Nazari et al. 2017 ). Therefore, not surprisingly, glycyrrhizin use has been associated with various side effects, such as the inhibition of the adrenal-pituitary axis, hypertension, and hypokalemic-induced conditions (Nazari et al. 2017) . Thus, these possible side effects may limit its use in PD, especially in elder patients with other comorbidities.
Since SNCA-HMGB1 binding seems to play an important role in autophagy impairment in PD, targeting this interaction presents a potential therapeutic strategy. Indeed, it has been revealed that the treatment of iPC12 cells with corynoxine B (Cory B), a natural autophagy enhancer, restored the impaired cytosolic translocation of HMGB1, as well as the deficient autophagy caused by over-expressed WT or mutant (A53T) SNCA. These results could be explained by the capacity of CoryB to weaken SNCA-HMGB1 interaction (Song et al. 2014) . This approach could be beneficial especially in familial PD cases caused by A53T mutations in SNCA gene.
Consequently, it is proposed that the use of molecules specifically targeting and inhibiting HMGB1, or SNCA-HMGB1 interaction may provide novel effective therapeutic strategies against PD, since HMGB1 is implicated in most pathophysiological processes involved in PD pathogenesis.
Conclusion and future perspectives
PD is considered as a multifactorial disorder, since genetic and environmental factors contribute to its development. Therefore, we can speculate, that not a single cause, but rather a combination of multiple pathophysiological mechanisms, including neuroinflammation, autophagy impairment, mitochondrial dysfunction, oxidative stress, and abnormal protein accumulation are associated with PD pathogenesis. Given the critical role of HMGB1 in most of these cellular processes described above, it is reasonable to speculate that it may represent at least one of the missing links bridging these pathogenic mechanisms.
Despite the evidence that HMGB1 is highly implicated in PD pathogenesis, via regulating neuroinflammation, autophagy, apoptosis, gene transcription, and possibly mitochondrial dysfunction and oxidative stress, the field is still in its infancy (Fig. 1) . Improved understanding of the molecular mechanisms involved in the effects of HMGB1 in PD pathogenesis could facilitate the design of effective treatment interventions. Important aspects that should be taken into account are probably the temporal pattern of HMGB1 release, the differential role of intracellular and extracellular HMGB1, the oxidative conditions of the microenvironment, as well as the potentially variable effects of HMGB1 upon its interaction with RAGE or TLRs in dopaminergic neurons and glial cells.
To the best of our knowledge, there has not been observed, a direct link between HMGB1 gene mutations and PD development. However, as described above, HMGB1 may be indirectly associated with the deleterious effects of A53T mutations in SNCA gene, via deregulation of autophagy. Moreover, aside from mutations in SNCA gene that cause autosomal dominant PD, mutations in PTEN-induced putative kinase 1 (PINK1) and Parkin have been associated with autosomal recessive PD. PINK1 and Parkin represent two key molecules in mitochondrial dysfunction observed in PD (Pickrell and Youle 2015) . Given the recent evidence that both Parkin and PINK1 are necessary for HMGB1-mediated mitophagy, an essential mechanism for the restoration of dysfunctional mitochondria (Tang et al. 2011a) , it is possible that HMGB1 may also be indirectly involved in the underlying cellular processes of genetic forms of PD caused by Parkin or PINK1 mutations.
HMGB1-based therapy may represent a powerful tool in PD and it may also prove useful for other synucleinopathies, such as Lewy body dementia (Lindersson et al. 2004) . Since neuroinflammation, autophagy, and mitochondrial dysfunction are implicated in several neurodegenerative diseases, such as Alzheimer Disease and amyotrophic lateral sclerosis, it is possible that HMGB1 may also be involved in these disorders.
Finally, it is important to note that SNCA has been observed to be secreted extracellularly by neuronal cells, and it has been hypothesized that spreading of SNCA pathology in a prion-like propagation manner could majorly contribute to PD pathogenesis (Poehler et al. 2014) . Therefore, given the fact that HMGB1 can also be secreted in the extracellular space by both neurons and glial cells, it would be of great interest to further investigate the possible effects of extracellular SNCA-HMGB1 interaction on PD progression.
